Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis

被引:0
作者
Yufu Peng
Kefei Chen
Bo Li
Hongwei Xu
Yonggang Wei
Fei Liu
机构
[1] West China Hospital of Sichuan University,Department of Liver Surgery, Center of Liver Transplantation
来源
Updates in Surgery | 2022年 / 74卷
关键词
Laparoscopic hepatectomy; Open hepatectomy; Hepatocellular carcinoma; BCLC stage B; Short-term outcomes; Survival rate;
D O I
暂无
中图分类号
学科分类号
摘要
To date, there is little knowledge about the value of laparoscopic liver resection (LLR) for hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer (BCLC) stage B. Thus, this study was performed to assess the perioperative and oncological outcomes of LLR for these patients by comparison with open liver resection (OLR). Between April 2015 and October 2018, a total of 217 resectable HCC patients with BCLC stage B were eligible for this study. Patients were divided into the LLR group and the OLR group according to different procedures. Propensity score matching (PSM) was conducted to adjust for known confounders. Short- and long-term outcomes were compared between the two groups. LLR was performed in 75 of the 217 included patients. After PSM, 72 patients with well-balanced baseline levels were enrolled into each group. Although the operative time was significantly longer in the LLR group than in the OLR group (median, 237.5 vs. 210 min, P = 0.024), the intraoperative blood loss was significantly less in the LLR group than in the OLR group (median, 200 vs. 350 ml, P = 0.005). Patients in the LLR group had fewer complications than those in the OLR group (P = 0.035). Furthermore, overall survival (OS, P = 0.827) and recurrence-free survival (RFS, P = 0.694) were comparable between the two groups. LLR for resectable HCC patients with BCLC stage B is safe and feasible in carefully selected patients and has superior perioperative outcomes and similar survival rates compared with OLR.
引用
收藏
页码:1291 / 1297
页数:6
相关论文
共 169 条
[1]  
Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2018)Hepatocellular carcinoma Lancet 391 1301-1314
[3]  
Siegel RL(2015)Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study Liver Int 35 2155-2166
[4]  
Laversanne M(2012)EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol. 56 908-943
[5]  
Soerjomataram I(2021)BCLC strategy for prognosis prediction and treatment recommendation barcelona clinic liver cancer (BCLC) staging system The 2022 update J Hepatol 61 82-88
[6]  
Jemal A(2014)Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond milan criteria: a RCT J Hepatol 62 617-624
[7]  
Forner A(2015)Survival benefit of liver resection for patients with hepatocellular carcinoma across different barcelona clinic liver cancer stages: a multicentre study J Hepatol 41 1153-1161
[8]  
Reig M(2015)Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: modern surgical resection as a feasible alternative to transarterial chemoemolization Eur J Surg Oncol 34 2155-2161
[9]  
Bruix J(2010)Comparing hepatic resection and transarterial chemoembolization for barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg 104 1045-1052
[10]  
Park JW(2017)Survival benefit of liver resection for barcelona clinic liver cancer stage B hepatocellular carcinoma Br J Surg 29 iv238-iv255